Analysts predict that Clearside Biomedical Inc (NASDAQ:CLSD) will report ($0.16) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Clearside Biomedical’s earnings, with estimates ranging from ($0.18) to ($0.15). Clearside Biomedical posted earnings of ($0.75) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 78.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 14th.
According to Zacks, analysts expect that Clearside Biomedical will report full year earnings of ($0.91) per share for the current year, with EPS estimates ranging from ($0.95) to ($0.88). For the next financial year, analysts expect that the firm will post earnings of ($0.42) per share, with EPS estimates ranging from ($0.63) to ($0.12). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Clearside Biomedical.
Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.22. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.05 million.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in Clearside Biomedical in the 2nd quarter worth $98,000. Paloma Partners Management Co bought a new position in Clearside Biomedical in the 2nd quarter worth $122,000. Vanguard Group Inc. raised its holdings in Clearside Biomedical by 66.9% in the 2nd quarter. Vanguard Group Inc. now owns 924,485 shares of the company’s stock worth $899,000 after purchasing an additional 370,690 shares in the last quarter. Finally, A.R.T. Advisors LLC bought a new position in Clearside Biomedical in the 2nd quarter worth $95,000. Institutional investors and hedge funds own 11.95% of the company’s stock.
NASDAQ:CLSD traded up $0.15 during midday trading on Wednesday, reaching $0.94. 3,541,789 shares of the stock traded hands, compared to its average volume of 784,938. The company has a fifty day moving average of $0.74 and a 200 day moving average of $1.03. Clearside Biomedical has a 12 month low of $0.56 and a 12 month high of $6.27. The company has a debt-to-equity ratio of 0.69, a quick ratio of 3.47 and a current ratio of 3.47. The stock has a market capitalization of $30.91 million, a P/E ratio of -0.35 and a beta of -0.57.
About Clearside Biomedical
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
See Also: What is a capital gain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.